These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 11176460

  • 1. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC, Steinberg GD.
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ.
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS.
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [Abstract] [Full Text] [Related]

  • 13. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S, Matsui Y, Takahashi T, Nishiyama H, Ito N, Yamamoto S, Kamoto T, Ogawa O.
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [Abstract] [Full Text] [Related]

  • 14. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 15. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
    Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM.
    J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD.
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [Abstract] [Full Text] [Related]

  • 19. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR.
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [Abstract] [Full Text] [Related]

  • 20. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N.
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.